Gamco Investors INC. ET AL bought a new stake in shares of Nevro Corp (NYSE:NVRO) during the 4th quarter, Holdings Channel reports. The fund bought 6,000 shares of the medical equipment provider’s stock, valued at approximately $414,000.

Several other institutional investors and hedge funds have also bought and sold shares of NVRO. Hershey Trust Co. purchased a new stake in Nevro in the fourth quarter worth $119,000. Ameritas Investment Partners Inc. grew its stake in Nevro by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 358 shares during the period. PNC Financial Services Group Inc. purchased a new stake in Nevro in the second quarter worth $190,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Nevro in the third quarter worth $211,000. Finally, Sterling Capital Management LLC purchased a new stake in Nevro in the second quarter worth $233,000.

Shares of Nevro Corp (NYSE:NVRO) opened at $75.99 on Wednesday. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59. Nevro Corp has a 1-year low of $65.00 and a 1-year high of $99.63. The company has a market capitalization of $2,238.71, a price-to-earnings ratio of -52.41 and a beta of -0.59.

NVRO has been the topic of several recent research reports. Northland Securities reaffirmed a “buy” rating and issued a $96.00 price target on shares of Nevro in a research note on Tuesday, November 7th. BidaskClub cut Nevro from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. ValuEngine cut Nevro from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Canaccord Genuity reduced their price target on Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, November 7th. Finally, TheStreet raised Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Nevro presently has a consensus rating of “Hold” and a consensus target price of $99.25.

WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2018/02/14/gamco-investors-inc-et-al-buys-new-position-in-nevro-corp-nvro.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.